HC Wainwright Has Bearish Forecast for BDTX Q1 Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Equities research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Black Diamond Therapeutics in a report issued on Tuesday, March 18th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their prior estimate of ($0.31). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.34) EPS and FY2025 earnings at ($1.32) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03.

A number of other research firms have also recently weighed in on BDTX. Stifel Nicolaus lowered their price objective on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $14.60.

Black Diamond Therapeutics Stock Performance

NASDAQ:BDTX opened at $1.88 on Thursday. The stock has a market capitalization of $106.52 million, a P/E ratio of -1.41 and a beta of 2.52. The company has a 50 day moving average price of $2.16 and a 200 day moving average price of $2.92. Black Diamond Therapeutics has a fifty-two week low of $1.59 and a fifty-two week high of $7.66.

Institutional Investors Weigh In On Black Diamond Therapeutics

Several institutional investors have recently modified their holdings of BDTX. Intech Investment Management LLC purchased a new stake in shares of Black Diamond Therapeutics during the 3rd quarter worth $56,000. Charles Schwab Investment Management Inc. lifted its position in shares of Black Diamond Therapeutics by 6.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 109,224 shares of the company’s stock worth $475,000 after purchasing an additional 7,021 shares during the last quarter. FMR LLC purchased a new stake in shares of Black Diamond Therapeutics during the 3rd quarter worth $779,000. MetLife Investment Management LLC lifted its position in shares of Black Diamond Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 22,286 shares of the company’s stock worth $97,000 after purchasing an additional 12,557 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Black Diamond Therapeutics during the 3rd quarter worth $49,000. 95.47% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Black Diamond Therapeutics

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the sale, the insider now directly owns 2,733,547 shares of the company’s stock, valued at approximately $5,658,442.29. The trade was a 67.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.87% of the stock is currently owned by corporate insiders.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.